Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

NCT04108858 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
HER2-Positive Breast Carcinoma
Metastatic Breast Carcinoma

Interventions

DRUG: Copanlisib
BIOLOGICAL: Pertuzumab
BIOLOGICAL: Trastuzumab

Sponsor

National Cancer Institute (NCI)